 Outlook Therapeutics Inc NASDAQ:OTLK announced the validation of the companys Marketing Authorization Application MAA by the European Medicines Agency EMA for an investigational ophthalmic formulation of bevacizumab ONS-5010 for the treatment of wet age-related macular degeneration wet AMD. The formal review process of the application by the EMAs committee for medicinal products for human use CHMP is now set to begin and an estimated decision date is expected in early 2024. 